Skip to main content

Advertisement

Table 1 Demographics, smoking history and spirometry. No statistically significant difference between study groups in within each trial

From: Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)

  Macro -BB Macro + BB Statcope -BB Statcope + BB
N 469 110 625 63
Age - years (SD) 64.6 (8.6) 67.3 (8.0) 62 (8.51) 63.4 (7.9)
Men - N (%) 273 (58.2%) 75 (67.6%) 349 (55.8%) 35 (55.6%)
Race
 % Black 16.8 11.7 20.3 25.4
 % White 79.5 82.9 77.1 73
Smoking History
 Pack years - mean (SD) 59.7 (33.7) 59.4 (28.5) 50.0 (26.3)* 49.1 (28.9)
 Current Smoker - % 22.4 21.6 30.6* 34.9
Spirometry - %
 GOLD 2 21.8 44.1 34.3 38.1
 GOLD 3 42.4 36 33.9 34.9
 GOLD 4 35.8 19.8 31.8 27
 FEV1 - Liters (SD) 1.09 (0.51) 1.31 (0.52) 1.20 (0.57)* 1.30 (0.62)
 FEV1 - mean % predicted value 38.3 46.8 41.8* 45.8
 FVC - Liters (SD) 2.61 (0.89) 2.81 (0.79) 2.68 (0.92) 2.65 (0.95)
 FVC - % predicted value 69.4 74.6 70.7 70.3
 FEV1/FVC 41.8 46.8 44.6 48.8
 Chronic Bronchitis - % 44.8 50.5 48.9 52.5
  1. * - p < 0.05 when compared with corresponding subgroup MACRO cohort